Home › Compare › PCQRF vs ABBV
PCQRF yields 2500.00% · ABBV yields 3.06%● Live data
📍 PCQRF pulled ahead of the other in Year 1
Combined, PCQRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PCQRF + ABBV for your $10,000?
Petrolympic Ltd. engages in the acquisition, exploration, and development of gold, petroleum, and natural gas properties in the United States and Canada. It holds a 100% interest covering an area of 55,951 hectares in the St. Lawrence Lowlands and Gaspe Peninsula; 30% interest of the 216,933 hectares with Ressources et Energie Squatex in the Utica Fairway and the underlying Trenton-Black River carbonates; and 12% interest of the total land package 8,000 hectares through an Agreement with Canbriam Energy. The company also holds 100% interest in the Mitis and the Matapedia properties covering an area of 41,014 hectares; and 30% interest in approximately 431,160 hectares through a joint venture with Squatex. In addition, it holds interest in the Vauquelin gold property that consists of 31 contiguous claims covering an area of 1,784 hectares located in the east of the Val d´Or mining camp, Quebec; and the Evangelic Lake Gold property that consists of 24 mining claims covering 600 hectares located in southwest of Espanola, Ontario. Further, the company has an agreement to acquire 100% interest in the Belcourt Gold property comprising 125 claims covering an area of 5,479 hectares situated near Val d'Or, Quebec; and the Rayon d'Or gold property that consists of two contiguous claims covering an area of 285.9 acres located in the east of the Val d´Or mining camp, Quebec. Petrolympic Ltd. is headquartered in Toronto, Canada.
Full PCQRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.